Opendata, web and dolomites

PREVMETSYN

SMALL MOLECULES TO TREAT METABOLIC SYNDROME

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PREVMETSYN" data sheet

The following table provides information about the project.

Coordinator
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) 

Organization address
address: ROBERT ROSSLE STRASSE 10
city: BERLIN
postcode: 13125
website: www.mdc-berlin.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙948 €
 EC max contribution 149˙948 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) DE (BERLIN) coordinator 149˙948.00

Map

 Project objective

SMALL MOLECULES TO TREAT METABOLIC SYNDROME Metabolic Syndrome (MS) is defined as a cluster of inter-related symptoms including central obesity, insulin resistance, dyslipidemia, and hypertension that promote the development of type 2 diabetes mellitus, cardiovascular diseases and certain cancers. In this project a pharmacological strategy will be developed that could alleviate the vicious circle of hyperglycemia (elevated blood glucose) and elevated insulin observed in metabolic syndrome that accelerates the onset of type 2 diabetes. We have identified a new protein that participates in insulin-dependent increase in glucose uptake from the blood. Loss of this protein leads to reduced insulin dependent glucose uptake and a metabolic syndrome like disease in mice. In this project small molecules that modulate the function of the said protein will be developed and evaluated. New molecules that enhance glucose uptake into cells could be potentially powerful new tools to reverse insulin resistance a key pathology of metabolic syndrome that can accelerate the onset of type 2 diabetes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREVMETSYN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREVMETSYN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More  

KEYNESGROWTH (2020)

Economic Fluctuations, Productivity Growth and Stabilization Policies: A Keynesian Growth Perspective

Read More  

Photopharm (2020)

Photopharmacology: From Academia toward the Clinic.

Read More